Nevro Corp (NVRO) Sets New 12-Month High at $81.03
Nevro Corp (NASDAQ:NVRO)’s share price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $81.03 and last traded at $80.47, with a volume of 437,836 shares traded. The stock had previously closed at $80.01.
A number of equities analysts have recently issued reports on NVRO shares. Wells Fargo & Co. started coverage on shares of Nevro Corp in a research report on Tuesday, July 12th. They set an “outperform” rating on the stock. Morgan Stanley reissued a “buy” rating and set a $86.00 price objective on shares of Nevro Corp in a research report on Wednesday, June 29th. Leerink Swann reissued a “buy” rating on shares of Nevro Corp in a research report on Monday, June 6th. Finally, William Blair started coverage on shares of Nevro Corp in a research report on Tuesday. They set an “outperform” rating on the stock.
The company’s market cap is $2.28 billion. The stock has a 50-day moving average price of $74.30 and a 200-day moving average price of $64.73.
In other Nevro Corp news, Director Michael F. Demane sold 13,333 shares of the business’s stock in a transaction on Friday, July 1st. The shares were sold at an average price of $74.00, for a total value of $986,642.00. Following the completion of the sale, the director now directly owns 519,253 shares of the company’s stock, valued at $38,424,722. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rami Elghandour sold 7,000 shares of the business’s stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $76.59, for a total transaction of $536,130.00. Following the completion of the sale, the chief executive officer now directly owns 71,180 shares of the company’s stock, valued at $5,451,676.20. The disclosure for this sale can be found here.
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.